Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment

被引:4
作者
Dedemadi, Anastasia-Georgia [1 ,2 ]
Gkolfinopoulou, Christina [1 ]
Nikoleri, Dimitra [3 ,4 ]
Nikoloudaki, Myrto [3 ]
Ruhanen, Hanna [5 ,6 ,7 ]
Holopainen, Minna [5 ,6 ,7 ]
Kakela, Reijo [6 ,7 ]
Christopoulou, Georgia [8 ]
Bournazos, Stavros [8 ]
Constantoulakis, Pantelis [8 ]
Sidiropoulos, Prodromos [3 ,4 ]
Bertsias, George [3 ,4 ]
Chroni, Angeliki [1 ]
机构
[1] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Athens 15341, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Chem, Athens, Greece
[3] Univ Crete, Med Sch, Lab Rheumatol Autoimmun & Inflammat, Iraklion, Greece
[4] FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece
[5] Univ Helsinki, Helsinki Inst Life Sci, Lipid Unit, HiLIPID, Helsinki, Finland
[6] Bioctr Finland, Helsinki, Finland
[7] Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Program, Helsinki, Finland
[8] Genotypos Sci Labs, Athens, Greece
关键词
systemic lupus erythematosus; biologicals; high-density lipoprotein; atheroprotection; lipidomic profile; CHOLESTEROL EFFLUX CAPACITY; ATHEROSCLEROSIS; FUNCTIONALITY;
D O I
10.1093/rheumatology/keae192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Chronic inflammatory diseases, like Systemic Lupus Erythematosus (SLE), carry an increased risk for atherosclerosis and cardiovascular events, accompanied by impairment of atheroprotective properties of high-density lipoprotein (HDL). In SLE, serum B cell-activating factor (BAFF), a cytokine implicated in disease progression, has been correlated with subclinical atherosclerosis. We investigated the impact of treatment with belimumab -an anti-BAFF monoclonal antibody- on HDL atheroprotective properties and composition in SLE patients.Methods Serum samples were collected from 35 SLE patients with active disease despite conventional therapy, before and after 6-month add-on treatment with belimumab, and 26 matched healthy individuals. We measured cholesterol efflux and antioxidant capacities, paraoxonase-1 (PON1) activity, serum amyloid A1 (SAA1), myeloperoxidase (MPO) and lipid peroxidation product levels of HDL. LC-MS/MS was performed to analyse the HDL lipidome.Results Following treatment with belimumab, cholesterol efflux and antioxidant capacities of HDL were significantly increased in SLE patients and restored to levels of control subjects. HDL-associated PON1 activity was also increased, whereas lipid peroxidation products were decreased following treatment. HDL cholesterol efflux and antioxidant capacities correlated negatively with the disease activity. Changes were noted in the HDL lipidome of SLE patients following belimumab treatment, as well as between SLE patients and healthy individuals, and specific changes in lipid species correlated with functional parameters of HDL.Conclusions HDL of SLE patients with active disease displays impaired atheroprotective properties accompanied by distinct lipidomic signatures compared with controls. Belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development. Graphical Abstract
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Effect Of Lipid Composition On The Atheroprotective Properties Of High-Density Lipoprotein-Mimicking Micelles
    Hong, Kristen W.
    Yu, Minzhi
    Mei, Ling
    Olsen, Karl
    Guo, Yanhong
    Luo, Yonghong
    Chen, Eugene
    Schwendeman, Anna
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42
  • [22] Successful treatment of refractory cystitis associated with systemic lupus erythematosus with Belimumab
    Xu, Liping
    Song, Xinwei
    Dai, Qiaoding
    Guan, Tianrong
    Zhang, Yan
    Lin, Na
    Wang, Ji-an
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 96
  • [23] Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease
    Lang, Maria G.
    Vinagre, Carmen G. C.
    Bonfa, Eloisa
    Freitas, Fatima R.
    Pasoto, Sandra G.
    Brito, Tatiane S.
    Seguro, Luciana P. C.
    Maranhao, Raul C.
    Borba, Eduardo F.
    LUPUS, 2022, 31 (06) : 659 - 665
  • [24] Different pregnancy outcomes in patients with systemic lupus erythematosus treated with belimumab
    Lai, Yupeng
    Li, Bin
    Huang, Jiaming
    Du, Jingning
    Yue, Mengli
    Shen, Xin
    Liu, Xingjiao
    Huang, Lingfeng
    Lin, Jiehua
    Yang, Aicheng
    Wang, Meiying
    LUPUS, 2023, 32 (01) : 149 - 154
  • [25] EFFECTIVENESS OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS OF A MULTICENTER SPANISH COHORT
    Altabas Gonzalez, I.
    Pego-Reigosa, J. M.
    Mourino Rodriguez, C.
    Jimenez, N.
    Hernandez-Martin, A.
    Casafont-Sole, I.
    Font, J.
    De La Rubia Navarro, M.
    Roman Ivorra, J. A.
    Galindo, M.
    Salman Monte, T. C.
    Vidal Montal, P.
    Narvaez, J.
    Garcia Villanueva, M. J.
    Piqueras Garcia, M. M.
    Fernandez Cid, C. Marras
    Martinez-Barrio, J.
    Sanchez Lucas, M.
    Penzo, E.
    Cortes-Hernandez, J.
    Alvarez Rodriguez, B.
    Vasques Rocha, M.
    Tomero Muriel, E.
    Menor-Almagro, R.
    Gandia Martinez, M.
    Frade-Sosa, B.
    Gomez-Puerta, J. A.
    Trapero, C.
    Ramos Giraldez, C.
    Moriano, C.
    Diez Alvarez, E.
    Munoz Jimenez, A.
    Rua-Figueroa, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 901 - 902
  • [26] High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus
    Juarez-Rojas, J. G.
    Medina-Urrutia, A. X.
    Posadas-Sanchez, R.
    Jorge-Galarza, E.
    Mendoza-Perez, E.
    Caracas-Portilla, N.
    Cardoso-Saldana, G.
    Munoz-Gallegos, G.
    Posadas-Romero, C.
    LUPUS, 2008, 17 (11) : 981 - 987
  • [27] Belimumab in the treatment of Portuguese systemic lupus erythematosus patients:a real-life multicenter study
    Fernandes, B. M.
    Barreira
    Fonseca, J. E.
    Cunha, M.
    Santos, M. J.
    Goncalves, N.
    Fernandes, A. L.
    Rodrigues, J.
    Fontes, T.
    Costa, L.
    Bernardes, M.
    ACTA REUMATOLOGICA PORTUGUESA, 2020, 45 (03): : 170 - 176
  • [28] EFFECT OF BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH MINIMAL OR NO STEROID
    Lee, Y. J.
    Ahn, S. M.
    Hong, S.
    Oh, J. S.
    Lee, C. K.
    Yoo, B.
    Kim, Y. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1474 - 1474
  • [29] Early effectiveness and safety analysis of belimumab in addition to standard treatment in patients with systemic lupus erythematosus
    He, Lingyan
    Yan, Mingming
    Wen, Rui
    Li, Jiali
    ARCHIVES OF RHEUMATOLOGY, 2024, 39 (02) : 172 - 179
  • [30] BELIMUMAB FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL WORLD: A SINGLE CENTER STUDY
    Fragio Gil, J. J.
    Martinez Calabuig, P.
    Salvador Maicas, L.
    Gonzalez Mazario, R.
    Rueda, A.
    Lerma, J. J.
    Molina Almela, C.
    Pastor Cubillo, M. D.
    Campos Fernandez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1478 - 1478